中华医学会肝病学分会、中华医学会感染病学分会. 《丙型肝炎防治指南》2015年更新版[J]. 实用肝脏病杂志, 2016, 19(4): 512-512.
| [1] Mohd Hanafiah K，Groeger J，Flaxman AD，et al. Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology，2013，57（4）:1333-42. [2] Lavanchy D. The global burden of hepatitis C[J]. Liver Int， 2009，29 Suppl 1:74-81. [3] WHO. Guidelines for the screening，care and treatment of persons with hepatitis infection. [4] Lemoine M，Nayagam S，Thursz M. Viral hepatitis in resource-limitedcountries and access to antiviral therapies:current and future challenges[J]. Future Virol，2013，8（4）:371-380。 [5] 陈圆生，李黎，崔富强，等. 中国丙型肝炎血清流行病学研究J. 中华流行病学杂志，2011，32（9）:888-891.。 [6] Rao H，Wei L，Lopez-Talavera JC，et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol，2014，29（3）:545-53. [7] Simmonds P，Bukh J，Combet C，et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005；42:962-973. [8] Lontok E，Harrington P，Howe A，et al. Hepatitis C virus drug resistance-associated substitutions:State of the art summary. Hepatology. 2015；Jun 10. doi:10.1002/hep.27934. [9] Farci P，Alter HJ，Wong D，et al. A long-term study of hepatitis C virus replication in non-A，non-B hepatitis[J]. N Engl J Med，1991，325（2）:98-104. [10] Corey KE，Mendez-Navarro J，Gorospe EC，et al. Early treatment improves outcomes in acute hepatitis C virus infection:a meta-analysis[J]. J Viral Hepat，2010，17（3）:201-207. [11] ChenSL，Morgan TR. The natural history of hepatitis C virus （HCV） infection[J].Int J MedSci，2006，3（2）:47-52. [12] Tillmann HL，Thompson AJ，Patel K，et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice[J]. Gastroenterology，2010，139（5）:1586-1592. [13] Kim AY，Kuntzen T，Timm J，et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes[J]. Gastroenterology，2011，140（2）:686-696. [14] Thursz M，Yallop R，Goldin R，et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus[J]. Lancet，1999，（9196）:2119-2124. [15] Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin[J]. N Engl J Med，1999， 340（16）:1228-1233. [16] Freeman AJ，Dore GJ， Law MG，et al. Hepatology. Estimating progression to cirrhosis in chronic hepatitis C virus infection[J]. Hepatolgy，2001，34（4 Pt 1）:809-816. [17] Li JF，Liu S，Ren F，et al. Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years:a cohort study[J]. Int J Infect Dis，2014，27:49-53. [18] Rao HY，Sun DG，Yang RF，et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors:a 12-19-year cohort study[J]. J Gastroenterol Hepatol，2012，27（3）:526-532. [19] Poynard T，Bedossa P，Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C[J]. Lancet，1997，349（9055）:825-832. [20] Barreiro P，Pineda JA，Rallón N，et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy[J]. J Infect Dis，2011，203（11）:1629-1636. [21] Ohki T，Tateishi R，Sato T，et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients[J]. Clin Gastroenterol Hepatol，2008，6（4）:459-464. [22] Milner KL，van der Poorten D，Trenell M，et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance[J]. Gastroenterology，2010，138（3）:932-941. [23] Kamal SM，Turner B，He Q，et al. Progression of fibrosis in hepatitis C with and without schistosomiasis:correlation with serum markers of fibrosis[J]. Hepatology，2006，43（4）:771-779. [24] El-Serag HB，Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis[J]. Gastroenterology，2007，132（7）:2557-2576. [25] Huang YW，Yang SS，Fu SC，et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes:a nationwide cohort study[J]. Hepatology，2014；60（3）:807-814. [26] Irshad M，Mankotia DS，Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J]. World J Gastroenterol，2013，19（44）:7896-7909. [27] Heim MH. Innate immunity and HCV[J]. J Hepatol，2013，58（3）:564-574. [28] Neumann AU，Lam NP，Dahari H，et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy[J]. Science，1998，282（5386）:103-107. [29] Thimme R，Oldach D，Chang KM，et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection[J]. J Exp Med，2001，194（10）:1395-1406. [30] Dowd KA，Netski DM，Wang XH，et alSelection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus[J]. Gastroenterology，2009，136（7）:2377-2386. [31] Dammacco F，Sansonno D，Piccoli C，et al. The lymphoid system in hepatitis C virus infection: autoimmunity，mixed cryoglobulinemia， and Overt B-cell malignancy[J].Semin Liver Dis，2000，20（2）:143-157. [32] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015，63（1）:199-236. [33] Long L，Shen T，Gao J，et al. Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coin fected patients. BMC Infect Dis. 2014 Nov 5;14:577. [34] 龙璐，刘媛，段昭君，等. 抗HCV抗体水平在不同HCV感染人群中的临床意义评价. 中华肝脏病杂志.22（4）: 244-250. [35] Omata M，Kanda T，Yu ML，et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012，6（2）:409-435. [36] Sarrazin C，Shiffman ML，Hadziyannis SJ，et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy[J]. J Hepatol，2010，52（6）:832-8. [37] Sarrazin C，Wedemeyer H，Cloherty G，et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy[J]. J Virol Methods，2015，214:29-32. [38] Simmonds P，Bukh J，Combet C，et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology，2005，42（4）:962-73. [39] Yang R，Cong X，Du S，et al. Performance comparison of the versant HCV genotype 2.0 assay （LiPA） and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6[J]. J Clin Microbiol，2014，52（10）:3685-92. [40] Thu Thuy PT，Bunchorntavakul C，Tan Dat H，et al. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C[J]. J Hepatol，2012，56（5）:1012-8. [41] Nelson DR，Cooper JN，Lalezari JP，et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study[J]. Hepatology，2015，61（4）:1127-35. [42] Abe H，Hayes CN，Hiraga N，et al. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing[J]. Am J Gastroenterol，2013，108（9）:1464-72. [43] Larrat S，Vallet S，David-TchoudaS，etal. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. J ClinMicrobiol. 2015 Jul；53（7）:2195-202. [44] Lawitz E，Sulkowski MS，Ghalib R，etal. Simeprevir plus sofosbuvir，with or without ribavirin，to treat chronic infection with hepatitis C virus genotype 1in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study. Lancet. 2014 Nov 15；384（9956）:1756-65. [45] European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015[J]. J Hepatol，2015，63（1）:199-236. [46] AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing，Managing，and Treating Adults Infected with Hepatitis C Virus[J]. Hepatology，2015；62（3）:932-954. [47] Masao Omata，Tatsuo Kanda，Ming-Lung Yu，etal. APASL consensus statements and management algorithmsfor hepatitis C virus infection. Hepatol Int，2012 Apr，6（2），409-435. [48] Geneva:World Health Organization. Guidelines for the Screening，Care and Treatment of Persons with Hepatitis C Infection. 2014 Apr（ISBN:978 92 4 154875 5）. [49] EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015；63（1）:237-64. [50] Wai CT，Greenson JK，Fontana RJ，et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003；38:518-26. [51] Castéra L，Sebastiani G，Le Bail B，de Lédinghen V，Couzigou P，Alberti A. Prospective comparison of two algorithms combining non-invasive methods forstaging liver fibrosis in chronic hepatitis C. J Hepatol. 2010；52（2）:191-8. [52] Martini A，Fattovich G，Guido M，et al. HCV genotype 3 and squamous cell carcinoma antigen（SCCA）-IgM are independently associated with histological features of NASH in HCV-infected patients[J]. J Viral Hepat，2015 Jan 22，doi:10.1111/jvh.12394. [Epub ahead of print]. [53] Macaluso FS，Maida M，Cammà C，et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C[J]. J Hepatol，2014，61（3）:523-9. [54] Moucari R，Ripault MP，Martinot-Peignoux M，et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4[J]. Gut，2009，58（12）:1662-9. [55] Poynard T，Moussalli J，Munteanu M，et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol，2013，59（4）:675-83. [56] Mohan P，Barton BA，Narkewicz MR，et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C:a retrospective study[J]. Hepatology，2013， 58（5）:1580-6. [57] Lambrecht RW，Sterling RK，Naishadham D，et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C[J]. Gastroenterology，2011，140（5）:1490-500. [58] D'Ambrosio R，Aghemo A，Fraquelli M，et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response[J]. J Hepatol，2013，59（2）:251-6. [59] Akhtar E，Manne V，Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy:a meta-analysis[J]. Liver Int，2015，35（1）:30-6. [60] D'Ambrosio R，Aghemo A，Rumi MG，et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J]. Hepatology，2012，56（2）:532-43. [61] Badossa P，Poynard T. An algorithm for the grading of activity in chronic hepatitis C[J]. Hepatology，1996，24:289-93. [62] Kim SU，Oh HJ，Wanless IR，et al. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis[J]. J Hepatol，2012，57（3）:556-63. [63] Huang Y，de Boer WB，Adams LA，et al. Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. J Hepatol，2014，61（1）:22-7. [64] Ding H，Ma JJ，Wang WP，et al. Assessment of liver fibrosis: the relationship between point shear wave elastography and quantitative histological analysis. J Gastroenterol Hepatol，2015，30（3）:553-8. [65] John-Baptiste AA，Tomlinson G，Hsu PC，et al. Sustained responders have betterquality of life and productivity compared with treatment failures long afterantiviral therapy for hepatitis C[J]. Am J Gastroenterol，2009，104（10）:2439-48. [66] Bunchorntavakul C，Maneerattanaporn M，Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease[J]. World J Hepatol，2015，7（2）:213-25. [67] El-Shabrawi M，Hassanin F. Treatment of hepatitis B and C in children[J]. Minerva Pediatr，2014，66（5）:473-89. [68] Morgan RL，Baack B，Smith BD，et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma:a meta-analysis of observational studies[J]. Ann Intern Med，2013，158（5 Pt 1）:329-37. [69] Backus LI，Boothroyd DB，Phillips BR，et al. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C[J]. Clin Gastroenterol H，2011，9（6）:509-U145. [70] van der Meer AJ，Veldt BJ，Feld JJ，et al. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis[J]. Jama-J Am Med Assoc，2012，308（24）:2584-93. [71] Nakamoto S，Kanda T，Shirasawa H，et al. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis[J]. World J Hepatol，2015，7（8）:1133-41. [72] Boccaccio V，Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals[J]. Liver Int，2014，34 Suppl 1:38-45. [73] Konerman MA，Mehta SH，Sutcliffe CG，et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults:prospective analysis of 435 liver biopsy pairs[J]. Hepatology，2014，59（3）:767-75. [74] Konstantinou D，Deutsch M. The spectrum of HBV/HCV coinfection:epidemiology，clinical characteristics，viralinteractions and management[J]. Ann Gastroenterol，2015，28（2）:221-8. [75] Michelotti GA，Machado MV，Diehl AM. NAFLD，NASH and liver cancer[J]. Nat Rev Gastroenterol Hepatol，2013，10（11）: 656-65. [76] Monje-Agudo P，Castro-Iglesias A，Rivero-Juarez A，et al. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin[J]. Eur J Clin Microbiol Infect Dis，2015，Jul 9. [Epub ahead of print]. [77] Marino Z，Londono MC，Forns X. Hepatitis C treatment for patients post liver transplant[J]. Curr Opin Organ Transplant，2015，20（3）:251-8. [78] Charlton M，Gane E，Manns MP，et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation[J]. Gastroenterology，2015，148（1）:108-17. [79] Agnello V，Chung RT，Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia[J]. N Engl J Med，1992，327（21）:1490-5. [80] Cacoub P，Terrier B，Saadoun D. Hepatitis C virus-induced vasculitis:therapeutic options[J]. Ann Rheum Dis，2014，73（1）: 24-30. [81] Johnson RJ，Gretch DR，Yamabe H，et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection[J]. N Engl J Med，1993，328（7）:465-70. [82] Paydas S. Hepatitis C virus and lymphoma[J]. Crit Rev Oncol Hematol，2015，93（3）:246-56. [83] Desouky DE，Kasemy Z，Abdel-Hamid AE，et al. Insulin Resistance and Prediabetes in Hepatitis C Virus Patients:A Cross-Sectional Case-Control Study[J]. Am J Med Sci，2015，350（2）:77-80. [84] Zornitzki T，Malnick S，Lysyy L，et al. Interferon therapy in hepatitis C leading to chronic type 1 diabetes[J]. World J Gastroenterol，2015，21（1）:233-9. [85] Gisbert JP，Garcia-Buey L，Pajares JM，et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda:systematic review and meta-analysis[J]. J Hepatol，2003，39（4）:620-7. [86] Racciatti D，Gorgoretti V，Sepede G，et al. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection:similarities and differences[J]. Int J Immunopathol Pharmacol，2011，24（3）:673-81. [87] Xu CJ，Zhang CP，Luo BF，et al. Prevalence and characterization of hepatitis B and C virus infections in a needle-sharing population in Northern China[J]. Bmc Public Health，2015，15:460. [88] Zou X，Chow EP，Zhao P，et al. Rural-to-urban migrants are at high risk of sexually transmitted and viral hepatitis infections in China:a systematic review and meta-analysis[J]. Bmc Infect Dis，2014，14:490. [89] Lambert J，Jackson V，Coulter-Smith S，et al. Universal antenatal screening for hepatitis C[J]. Ir Med J，2013，106（5）:136-9. [90] Fissell RB，Bragg-Gresham JL，Woods JD，et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents:The DOPPS. Kidney International[J]. 2004，65（6）:2335-42. [91] Post JJ，Arain A，Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting[J]. Clin Infect Dis，2013，57 Suppl 2:S70-4. [92] Leidner AJ，Chesson HW，Xu F，et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease[J]. Hepatology，2015，61（6）:1860-9. [93] Puoti C，Bellis L，Guarisco R，et al. HCV carriers with normal alanine aminotransferase levels:healthy persons or severely ill patients Dealing with an everyday clinical problem[J]. Eur J Intern Med，2010，21（2）:57-61. [94] EASL Clinical Practice Guideline.Management of hepatitis C virus infection[J]. J Hepaology，2011，55（2）:245-264. [95] 中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南[J]. 中华内科杂志，2004，43（7）：551-555. [96] 中国国家处方集编委会。《中国国家处方集》人民军医出版社 2010年. [97] 魏来主编. 《丙型肝炎-临床诊断与治疗手册》[M]. 科学出版社 2012年. [98] Awad T，Thorlund K，Hauser G，et al. Proceed with caution peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C[J]. Hepatology，2010，52（6）:2241-2242. [99] 陈新月，尚佳，杨瑞锋，等.难治性慢性丙型肝炎初治患者优化治疗后的高病毒学应答率[J]. 中华肝脏病杂志，2015，23（6）：412-417. [100]EASL Clinical Practice Guideline.Management of hepatitis C virus infection[J]. J Hepaology，2014，60（2）:392-420. [101]饶慧瑛，杨瑞锋，尚佳， 等. 不同疗程聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎复发患者的疗效比较及影响因素. 中华内科杂志. 2015，54（8）:699-704.） [102]Singal AG，Waljee AK，Shiffman M，et al. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy[J]. Aliment Pharmacol Ther，2010，32（8）:969-983.） [103]尚佳， 徐小元，陈新月，等. 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎无应答患者的疗效及影响因素. 中华临床感染病杂志. 2015， 8（3）:232-237.） [104]Cammà C，Cabibbo G，Bronte F，et al. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin:a meta-analysis[J]. J Hepatol，2009，51（4）:675-81. [105]Wei L，Han T，Yang D，et al. Simeprevir plus peginterferon/ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection:Results from the Phase III TIGER study conducted in East Asian patients living in China and Korea[J]. Hepatol Int，2015，9（S1）:S61. [106]Lawitz E，Mangia A，Wyles D，et al. Sofosbuvir for previously untreated chronic hepatitis C infection[J]. N Engl J Med，2013，368（20）:1878-1887. [107]Mishra P，Florian J，Qi K，et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin[J]. Gastroenterology，2014，147（6）:1196-1200. [108]Afdhal N， Zeuzem S，Kwo P，et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J]. N Engl J Med，2014，370（20）:1889-1898. [109]Afdhal N，Reddy KR，Nelson DR，et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J]. N Engl J Med，2014，370（16）:1483-1493. [110]Kowdley KV，Gordon SC，Reddy KR，et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J]. N Engl J Med，2014，370（20）:1879-1888. [111]Feld JJ，Kowdley KV，Coakley E，et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med，2014，370（17）:1594-1603. [112]Ferenci P，Bernstein D，Lalezari J，et al. ABT-450/rombitasvirand dasabuvir with or without ribavirin for HCV[J]. N Engl J Med，2014，370（21）:1983-1992. [113]Zeuzem S，Jacobson IM，Baykal T，et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir withribavirin[J]. N Engl J Med，2014，370（17）:1604-1614. [114]Andreone P，Colombo MG，Enejosa JV，et al. ABT-450，ritonavir，ombitasvir，and dasabuvir achieves 97% and 100%sustained virologic response with or without ribavirin in treatmentexperiencedpatients with HCV genotype 1b infection[J]. Gastroenterology，2014，147（2）:359-365. [115]Poordad F，Hezode C，Trinh R，et al. ABT450/r-ombitasvirand dasabuvir with ribavirin for hepatitis C with cirrhosis[J]. N Engl J Med，2014（21），370:1973-1982. [116]Sulkowski MS，Gardiner DF，Rodriguez-Torres M，et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J]. N Engl J Med，2014，370（3）:211-221. [117]Kumada H，Suzuki Y，Ikeda K，Toyota J，Karino Y，Chayama K，et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology，2014；59:2083-91. [118]Lawitz E，Mangia A，Wyles D，et al. Sofosbuvir for previously untreated chronic hepatitis C infection[J]. N Engl J Med，2013，368（20）:1878-1887. [119]Zeuzem S，Dusheiko GM，Salupere R，et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J]. N Engl J Med，2014，370（21）:1993-2001. [120]Pol S，Reddy KR，Baykal T，et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection:PEARL-I study results[J]. Hepatology，2014，60:1129A. [121]Gane EJ，Hyland RH，An D，et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection[J]. Hepatology，2014；60:1274A. [122]Hu J，Doucette K，Hartling L，et al. Treatment of hepatitisC in children:a systematic review[J]. PloS One，2010，5（7）:e11542. [123]Hartwell D，Cooper K，Frampton GK，et al. The clinical effectiveness and cost-effectiveness of peginterferonalfa and ribavirin for the treatment of chronic hepatitis C in children and young people:a systematic review and economic evaluation[J]. Health Technol Assess，2014，18（65）:i-xxii，1-202. [124]Sulkowski MS，Thomas DL，Mehta SH，et al. Hepatotoxicityassociated with nevirapine or efavirenz-containing antiretroviral therapy:Role of hepatitis C and B infections[J]. Hepatology，2002，35（1）:182-189. [125]Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity[J]. Hepatology，2010，52（3）:1143-55. [126]Fabrizi F，Dixit V，Messa P，et al. Antiviral therapy （pegylated interferon and ribavirin） of hepatitis C in dialysis patients:meta-analysis of clinical studies[J]. Journal of Viral Hepatitis，2014，21（10）:681-689. [127]Scott DR，Wong JK，Spicer TS，et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand[J].Transplantation，2010，90（11）:1165-1171. [128]Singal AG，Volk ML，Jensen D，et al. A sustainedviral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus[J]. Clin Gastroenterol Hepatol，2010，8（3）:280-288. [129]van der Meer AJ，Veldt BJ，Feld JJ，et al. Association between sustained virological response and all-cause mortalityamong patients with chronic hepatitis C and advanced hepatic fibrosis[J]. JAMA，2012，308（24）:2584-2593. [130]Afdhal N，Everson G，Calleja JL，et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation:early virologic response and safety[J]. J Hepatol 2014，60:S28. [131]Kevans，D，Farrell G，Hopkins S，et al. Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes[J]. Haemophilia，2007，13（5）:593-8. [132]Monaco S，Ferrari S，Gajofatto A，et al. HCV-Related Nervous System Disorders[J]. Clinical & Developmental Immunology，2012，2012:236148. [133]van der Meer，A.J. Achieving sustained virological response:what's the impact on further hepatitis C virus-related disease [J] Expert Review of Gastroenterology & Hepatology，2015，9（5）: 559-566. [134]Papatheodoridis G，Buti M，Cornberg M，et al. EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus infection. Journal of Hepatology. Jul 2012；57（1）:167-185. [135]Liu，C.J. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues[J]. Journal of Gastroenterology and Hepatology，2014，29（1）:26-30. [136]Rodriguez-Torres M，Slim J，Bhatti L，et al. Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients:A Randomized International Trial[J]. Hiv Clinical Trials，2012，13（3）:142-152. [137]Micallef JM，Kaldor JM，Dore GJ. Spontaneous viral clearance following acute hepatitis C infection:a systematic review of longitudinal studies[J]. Journal of Viral Hepatitis，2006，13（1）:34-41. [138] Hofer H，Watkins-Riedel T，Janata O，et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load[J]. Hepatology，2003，37（1）:60-64. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
